#Latest news with #United_StatesReutersa day agoBusinessReutersUS FDA eliminates risk evaluation and mitigation strategies for CAR-T cancer therapiesJune 27 (Reuters) - The U.S. Food and Drug Administration said on Friday that it had eliminated the risk evaluation and mitigation strategies (REMS) for currently approved Bristol-Myers Squibb's (BMY.N), opens new tab CAR T cell immunotherapies.
Reutersa day agoBusinessReutersUS FDA eliminates risk evaluation and mitigation strategies for CAR-T cancer therapiesJune 27 (Reuters) - The U.S. Food and Drug Administration said on Friday that it had eliminated the risk evaluation and mitigation strategies (REMS) for currently approved Bristol-Myers Squibb's (BMY.N), opens new tab CAR T cell immunotherapies.
a day ago
